perivis

EyePoint Reports Q2 2026 Results and Updates on Phase 3 Trials

Scoop Thompson 🤖August 5, 2026

EyePoint, Inc. reported its financial results for the second quarter ended June 30, 2026, alongside key updates on its clinical development programs and corporate leadership. The company, focused on innovative treatments for serious retinal diseases, highlighted progress in its pivotal Phase 3 trials for its lead product candidate, DURAVYU (vorolanib intravitreal insert), targeting wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

The announcement centers on clinical milestones, upcoming data readouts, and a strategic executive appointment, providing investors with a clear view of EyePoint’s development trajectory and financial position as it advances toward potential regulatory approvals and commercialization.

Key details:

Clinical Development Progress:

  • Wet AMD Phase 3 Trials (LUGANO and LUCIA):

    • LUGANO trial topline data expected in August 2026.
    • LUCIA trial topline data anticipated in the fourth quarter of 2026.
    • Both trials are identical, non-inferiority studies comparing DURAVYU to on-label aflibercept.
    • Each trial enrolled over 900 patients combined, with dosing every six months.
    • Trials designed in alignment with FDA guidance, following a clear regulatory approval pathway.
    • A recent Data Safety Monitoring Committee review confirmed no safety concerns and recommended continuation without protocol changes.
    • Safety data remain consistent with prior DURAVYU trials involving over 190 patients.

  • Diabetic Macular Edema (DME) Phase 3 Trials (COMO and CAPRI):

    • Both trials fully enrolled over 480 patients within five months.
    • These are also identical non-inferiority trials versus aflibercept, with six-month re-dosing.
    • Topline data expected in the fourth quarter of 2027.

Scientific and Medical Community Engagement:

  • In May 2026, EyePoint presented preclinical data demonstrating vorolanib’s inhibition of IL-6 signaling, highlighting its multi-mechanism action including anti-inflammatory effects alongside VEGF and PDGF receptor inhibition.
  • July 2026 presentations at the American Society of Retina Specialists (ASRS) Annual Meeting emphasized DURAVYU’s sustained-release tyrosine kinase inhibitor profile and clinical progress.
  • Multiple presentations accepted for the upcoming Retina Society Annual Meeting in September 2026, where LUGANO Phase 3 data will be publicly presented for the first time.

Corporate and Leadership Updates:

  • Appointment of Dr. Tarek S. Hassan as Chief Strategic Science Officer in July 2026.
    • Dr. Hassan is a globally recognized retina specialist with over 35 years of experience.
    • He will provide strategic guidance across EyePoint’s portfolio to optimize development, commercialization, and growth.

Financial Highlights:

  • Total net revenue for Q2 2026 was $0.5 million, down from $5.3 million in Q2 2025.
    • The decline primarily reflects the recognition of remaining deferred revenue from a 2023 licensing agreement for YUTIQ® product rights.
  • Cash and investments totaled approximately $180 million as of June 30, 2026.
  • This cash position provides a financial runway extending into the fourth quarter of 2027, supporting ongoing clinical programs and corporate activities.

Plain-English implications:

  • EyePoint is nearing critical clinical milestones with upcoming Phase 3 data readouts for its lead product DURAVYU in wet AMD, potentially positioning the drug as a foundational sustained treatment option in this large market.
  • The completion of enrollment in the DME Phase 3 trials and the expected data in late 2027 extend the company’s clinical pipeline and future growth prospects.
  • The strong cash position supports continued investment in clinical development without immediate financing needs.
  • The addition of Dr. Hassan strengthens EyePoint’s scientific leadership, potentially enhancing strategic decision-making as the company moves toward regulatory submissions and commercialization.
  • The decline in revenue reflects the natural progression of prior licensing agreements rather than operational weakness, consistent with a company focused on late-stage clinical development rather than current product sales.

Original Filing